JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
作者： A Pardanani , A M Vannucchi , F Passamonti , F Cervantes , T Barbui
DOI: 10.1038/LEU.2010.269
关键词:
摘要: … We discuss below the prevalence, current treatment and therapeutic value of JAK inhibitors, in … For the purposes of the current perspective, we focus on three JAK inhibitors with the most …
elsevier.com
nature.com
sci-hub.se 参考文章(71)
Ruben A. Mesa, Joyce Niblack, Martha Wadleigh, Srdan Verstovsek, John Camoriano, Sunni Barnes, Angelina D. Tan, Pamela J. Atherton, Jeff A. Sloan, Ayalew Tefferi, The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. ,vol. 109, pp. 68- 76 ,(2007) , 10.1002/CNCR.22365
Alessandro Rambaldi, Chiara Maria Dellacasa, Guido Finazzi, Alessandra Carobbio, Maria Luisa Ferrari, Paola Guglielmelli, Elisabetta Gattoni, Silvia Salmoiraghi, Maria Chiara Finazzi, Silvia Di Tollo, Carmine D’Urzo, Alessandro M. Vannucchi, Giovanni Barosi, Tiziano Barbui, A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms British Journal of Haematology. ,vol. 150, pp. 446- 455 ,(2010) , 10.1111/J.1365-2141.2010.08266.X
Thomas Ernst, Andrew J Chase, Joannah Score, Claire E Hidalgo-Curtis, Catherine Bryant, Amy V Jones, Katherine Waghorn, Katerina Zoi, Fiona M Ross, Andreas Reiter, Andreas Hochhaus, Hans G Drexler, Andrew Duncombe, Francisco Cervantes, David Oscier, Jacqueline Boultwood, Francis H Grand, Nicholas C P Cross, Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nature Genetics. ,vol. 42, pp. 722- 726 ,(2010) , 10.1038/NG.621
N Carbuccia, A Murati, V Trouplin, M Brecqueville, J Adelaide, J Rey, W Vainchenker, OA Bernard, M Chaffanet, N Vey, D Birnbaum, MJ Mozziconacci, Mutations of ASXL1 gene in myeloproliferative neoplasms Leukemia. ,vol. 23, pp. 2183- 2186 ,(2009) , 10.1038/LEU.2009.141
Jocelin Huang, Ayalew Tefferi, Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. European Journal of Haematology. ,vol. 83, pp. 154- 155 ,(2009) , 10.1111/J.1600-0609.2009.01266.X
Robert Kralovics, Francesco Passamonti, Andreas S. Buser, Soon-Siong Teo, Ralph Tiedt, Jakob R. Passweg, Andre Tichelli, Mario Cazzola, Radek C. Skoda, A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders The New England Journal of Medicine. ,vol. 352, pp. 1779- 1790 ,(2005) , 10.1056/NEJMOA051113
A M Vannucchi, E Antonioli, P Guglielmelli, A Pardanani, A Tefferi, Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. ,vol. 22, pp. 1299- 1307 ,(2008) , 10.1038/LEU.2008.113
Ayalew Tefferi, Kristi J. Smock, Ajit B. Divgi, Polycythemia vera‐associated acquired von Willebrand syndrome despite near‐normal platelet count American Journal of Hematology. ,vol. 85, pp. 545- 545 ,(2010) , 10.1002/AJH.21730
A Pardanani, T L Lasho, C Finke, C A Hanson, A Tefferi, Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. ,vol. 21, pp. 1960- 1963 ,(2007) , 10.1038/SJ.LEU.2404810
A Tefferi, T L Lasho, R A Mesa, A Pardanani, R P Ketterling, C A Hanson, Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. ,vol. 21, pp. 1827- 1828 ,(2007) , 10.1038/SJ.LEU.2404711